Jump Financial LLC Sells 24,736 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL)

Jump Financial LLC decreased its holdings in shares of Castle Biosciences, Inc. (NASDAQ:CSTL - Free Report) by 68.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 11,400 shares of the company's stock after selling 24,736 shares during the quarter. Jump Financial LLC's holdings in Castle Biosciences were worth $304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in CSTL. Advisors Capital Management LLC increased its holdings in shares of Castle Biosciences by 6.6% during the 4th quarter. Advisors Capital Management LLC now owns 178,935 shares of the company's stock worth $4,769,000 after purchasing an additional 11,008 shares during the period. Next Century Growth Investors LLC grew its position in Castle Biosciences by 0.5% during the fourth quarter. Next Century Growth Investors LLC now owns 235,214 shares of the company's stock worth $6,268,000 after buying an additional 1,123 shares in the last quarter. Covestor Ltd bought a new position in Castle Biosciences during the fourth quarter valued at about $25,000. Renaissance Technologies LLC increased its stake in Castle Biosciences by 39.9% during the fourth quarter. Renaissance Technologies LLC now owns 685,000 shares of the company's stock valued at $18,255,000 after acquiring an additional 195,438 shares during the period. Finally, Invesco Ltd. raised its holdings in Castle Biosciences by 2.3% in the 4th quarter. Invesco Ltd. now owns 27,534 shares of the company's stock valued at $734,000 after acquiring an additional 616 shares in the last quarter. Institutional investors and hedge funds own 92.60% of the company's stock.

Insider Transactions at Castle Biosciences

In related news, insider Derek J. Maetzold sold 22,639 shares of Castle Biosciences stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $20.12, for a total value of $455,496.68. Following the completion of the sale, the insider now directly owns 80,465 shares in the company, valued at $1,618,955.80. This trade represents a 21.96 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Daniel Bradbury sold 7,867 shares of the company's stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $28.17, for a total transaction of $221,613.39. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 35,321 shares of company stock worth $774,644. Insiders own 7.20% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on CSTL. Stephens reaffirmed an "overweight" rating and issued a $41.00 target price on shares of Castle Biosciences in a research report on Thursday, January 2nd. Guggenheim set a $30.00 price target on Castle Biosciences and gave the company a "buy" rating in a research note on Friday, March 28th. Finally, Robert W. Baird increased their price objective on Castle Biosciences from $36.00 to $37.00 and gave the stock an "outperform" rating in a research note on Friday, February 28th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $38.75.

Castle Biosciences Price Performance

CSTL stock traded down $0.12 during midday trading on Friday, reaching $19.19. 461,847 shares of the company's stock traded hands, compared to its average volume of 437,190. The company has a 50-day simple moving average of $20.54 and a two-hundred day simple moving average of $26.29. The company has a quick ratio of 7.64, a current ratio of 7.78 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a 1-year low of $16.97 and a 1-year high of $35.84. The company has a market cap of $553.54 million, a price-to-earnings ratio of 95.83 and a beta of 1.11.

About Castle Biosciences

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.